OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax(TM) in Mexico

Pharmaceutical Investing
Company News

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance from the Mexican Institute of Industrial Property for OncBioMuneā€™s patent application number MX/a/2013/008188.

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance from the Mexican Institute of Industrial Property for OncBioMuneā€™s patent application number MX/a/2013/008188. The patent covers ProscaVaxā„¢, OncBioMuneā€™s novel cancer vaccine in clinical development, as a composition and method for treating cancer.
ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune and its Mexican Joint Venture partner Vitel Laboratorios S.A. de C.V. (ā€œVitelā€) are sponsoring a Phase 2/3 clinical study of ProscaVax in Mexico evaluating the vaccine as a new treatment for recurrent prostate cancer in hormone-naĆÆve and hormone-independent patients.
ā€œWe are very pleased to receive notice of allowance of another patent covering ProscaVax. The patent in Mexico is particularly important because if the endpoints are met in the Phase 2/3 study, we intend to seek marketing approval through Mexicoā€™s expedited approval process,ā€ commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. ā€œMoreover, as with other patents pertaining to ProscaVax, the patent claims are broad enough to cover many other types of cancer that we intend to research in Mexico in the future.ā€
The latest patent expands the protection of ProscaVax and other OncBioMune intellectual property to 16 patents spanning approximately 50 countries worldwide.
Connect withĀ OncBioMune Pharmaceuticals (OTCMKTS:OBMP) Ā to receive an Investor Presentation.

The Conversation (0)
Ɨ